Financials Dr. Reddy's Laboratories Limited NSE India S.E.

Equities

DRREDDY

INE089A01023

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 07:43:53 2024-07-12 am EDT			5-day change	1st Jan Change
6,719 ^INR	+1.89%		+3.06%	+15.89%

Jul. 10	Asian Equities Traded in the US as American Depositary Receipts Climb Higher in Wednesday Trading	MT
Jul. 08	Asian Equities Traded in the US as American Depositary Receipts Open Week Slightly Higher in Monday Trading	MT

Valuation

Fiscal Period: March	2020	2021	2022	2023	2024	2025	2026	2027
Capitalization ¹	516,741	749,317	714,500	767,655	1,024,969	1,119,423	-	-
Enterprise Value (EV) ¹	513,012	745,052	703,980	719,330	960,383	1,030,226	994,666	956,285
P/E ratio	26.6 x	39.2 x	30.4 x	17.1 x	18.4 x	20.2 x	19.6 x	23.3 x
Yield	0.8%	0.55%	0.7%	0.87%	0.65%	0.59%	0.6%	0.55%
Capitalization / Revenue	2.96 x	3.95 x	3.33 x	3.11 x	3.66 x	3.7 x	3.44 x	3.49 x
EV / Revenue	2.94 x	3.93 x	3.28 x	2.92 x	3.43 x	3.41 x	3.06 x	2.98 x
EV / EBITDA	11 x	15.7 x	13.7 x	11.1 x	12.1 x	12.2 x	11.4 x	12.5 x
EV / FCF	20.5 x	28.7 x	52.3 x	15.1 x	33.1 x	21.9 x	20.6 x	19.9 x
FCF Yield	4.87%	3.48%	1.91%	6.61%	3.02%	4.57%	4.85%	5.01%
Price to Book	3.33 x	4.29 x	3.76 x	3.33 x	3.63 x	3.44 x	2.99 x	2.67 x
Nbr of stocks (in thousands)	165,776	165,940	165,954	166,105	166,522	166,540	-	-
Reference price ²	3,117	4,516	4,305	4,622	6,155	6,722	6,722	6,722
Announcement Date	6/9/20	5/14/21	5/19/22	5/10/23	5/7/24	-	-	-

¹INR in Million²INR

Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March	2020	2021	2022	2023	2024	2025	2026	2027
Net sales ¹	174,600	189,722	214,391	246,697	280,111	302,322	325,109	320,836
EBITDA ¹	46,431	47,480	51,400	64,559	79,481	84,257	87,572	76,465
EBIT ¹	28,470	31,977	34,277	52,057	64,781	68,921	71,063	59,316
Operating Margin	16.31%	16.85%	15.99%	21.1%	23.13%	22.8%	21.86%	18.49%
Earnings before Tax (EBT) ¹	18,032	28,324	32,298	60,485	72,010	73,790	76,033	63,039
Net income ¹	19,498	19,149	23,568	45,073	55,779	55,118	56,848	48,376
Net margin	11.17%	10.09%	10.99%	18.27%	19.91%	18.23%	17.49%	15.08%
EPS ²	117.4	115.1	141.7	270.9	334.6	332.3	342.6	288.8
Free Cash Flow ¹	24,995	25,962	13,448	47,552	29,030	47,058	48,212	47,942
FCF margin	14.32%	13.68%	6.27%	19.28%	10.36%	15.57%	14.83%	14.94%
FCF Conversion (EBITDA)	53.83%	54.68%	26.16%	73.66%	36.52%	55.85%	55.05%	62.7%
FCF Conversion (Net income)	128.19%	135.58%	57.06%	105.5%	52.04%	85.38%	84.81%	99.1%
Dividend per Share ²	25.00	25.00	30.00	40.00	40.00	39.90	40.37	36.82
Announcement Date	6/9/20	5/14/21	5/19/22	5/10/23	5/7/24	-	-	-

¹INR in Million²INR

Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2025 Q1	2025 Q2	2025 Q3	2025 Q4
Net sales ¹	53,197	54,368	52,154	63,057	67,700	63,152	67,384	68,802	72,148	71,138	72,989	75,511	76,562	79,441
EBITDA ¹	12,018	12,980	9,238	18,944	20,562	15,955	20,450	19,915	20,180	18,174	19,838	20,864	20,370	21,246
EBIT ¹	9,042	8,743	6,188	15,818	17,291	12,800	16,867	16,126	16,410	14,497	16,442	17,108	16,884	16,983
Operating Margin	17%	16.08%	11.86%	25.09%	25.54%	20.27%	25.03%	23.44%	22.74%	20.38%	22.53%	22.66%	22.05%	21.38%
Earnings before Tax (EBT) ¹	9,709	2,483	14,655	16,111	16,346	13,291	18,463	19,134	18,257	16,052	17,018	17,634	17,190	17,918
Net income ¹	7,065	875	11,876	11,128	12,471	9,601	14,025	14,800	13,789	13,098	13,020	13,326	12,980	13,550
Net margin	13.28%	1.61%	22.77%	17.65%	18.42%	15.2%	20.81%	21.51%	19.11%	18.41%	17.84%	17.65%	16.95%	17.06%
EPS ²	42.48	5.260	71.40	66.89	74.95	57.68	84.22	88.78	82.68	78.53	77.05	-	-	-
Dividend per Share	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Announcement Date	1/28/22	5/19/22	7/28/22	10/28/22	1/25/23	5/10/23	7/26/23	10/27/23	1/30/24	5/7/24	-	-	-	-

¹INR in Million²INR

Estimates

Balance Sheet Analysis

Fiscal Period: March	2020	2021	2022	2023	2024	2025	2026	2027
Net Debt ¹	-	-	-	-	-	-	-	-
Net Cash position ¹	3,729	4,265	10,520	48,325	64,586	89,197	124,757	163,138
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-	-
Free Cash Flow ¹	24,995	25,962	13,448	47,552	29,030	47,058	48,212	47,942
ROE (net income / shareholders' equity)	13.2%	11.6%	13%	21.4%	21.6%	17.9%	16%	12%
ROA (Net income/ Total Assets)	8.52%	7.69%	8.39%	14.7%	15.7%	12.4%	11.3%	9.54%
Assets ¹	228,823	248,866	281,073	307,340	355,745	444,404	503,098	507,046
Book Value Per Share ²	935.0	1,052	1,145	1,387	1,694	1,955	2,250	2,513
Cash Flow per Share ²	180.0	215.0	169.0	354.0	272.0	397.0	419.0	394.0
Capex ¹	4,846	9,741	14,660	11,323	16,403	16,382	16,403	17,218
Capex / Sales	2.78%	5.13%	6.84%	4.59%	5.86%	5.42%	5.05%	5.37%
Announcement Date	6/9/20	5/14/21	5/19/22	5/10/23	5/7/24	-	-	-

¹INR in Million²INR

Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Dr. Reddy's Laboratories Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

6,722 INR

Average target price

6,167 INR

Spread / Average Target

-8.25%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+62.66%	854B
NOVO NORDISK A/S	+40.42%	636B
JOHNSON & JOHNSON	-4.37%	361B
MERCK & CO., INC.	+17.16%	324B
ABBVIE INC.	+9.87%	301B
ASTRAZENECA PLC	+15.66%	247B
ROCHE HOLDING AG	+4.21%	230B
NOVARTIS AG	+17.90%	228B
AMGEN INC.	+14.86%	177B

Other Pharmaceuticals